CytoDyn settles Class Action Lawsuit

CytoDyn, a clinical-stage oncology company, has recently finalized an agreement to settle a securities class action lawsuit that was initiated in March 2021 against the Company and certain former officers. The case, titled Courter et al. v. CytoDyn Inc. et al., is currently pending in the United States District Court for the Western District of Washington.

The agreement in principle was reached by the parties involved on November 23, 2025, and is awaiting final court approval. Additional details regarding this resolution can be found in the Company’s recent Form 8-K filing with the Securities and Exchange Commission (SEC) on December 1, 2025, and will be further disclosed in subsequent reports submitted to the SEC.

Tyler Blok, Chief Legal Officer at CytoDyn, expressed that the settlement brings clarity and closure to the matter, benefiting all of the Company’s stakeholders, including stockholders and potential pharmaceutical partners. Pending final court approval of the settlement, the Company aims to conclude this issue and shift focus towards advancing their clinical development programs.

Jacob Lalezari, M.D., CEO of CytoDyn, emphasized the importance of resolving this matter promptly. He highlighted the significance of providing stockholders with the closure they deserve, stating that the resolution underscores the Company’s stability and enables them to pursue their mission effectively. This resolution comes at a pivotal time for CytoDyn, coinciding with a growing body of clinical evidence reinforcing the therapeutic potential of leronlimab.

Leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor, holds promise across various indications, including metastatic triple-negative breast cancer (mTNBC) and colorectal cancer (mCRC). The Company’s ongoing commitment to advancing leronlimab aligns with its mission to improve patients’ quality of life through innovative therapies.

CytoDyn’s dedication to developing a versatile platform to address unmet medical needs across multiple markets underscores its integrity, responsibility, and service-oriented approach. As they continue to progress with new Phase II studies in metastatic colorectal cancer and metastatic triple-negative breast cancer, as well as their Expanded Access Program, CytoDyn remains optimistic about leronlimab’s potential to offer significant benefits to cancer patients with limited treatment options.

In conclusion, the resolution of the securities class action lawsuit marks a pivotal moment for CytoDyn, setting the stage for the Company to advance its clinical development programs with renewed focus and determination. The agreement reached underscores CytoDyn’s commitment to transparency, stability, and its overarching mission to bring transformative treatments to patients globally.